InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative and Chronic Spontaneous Urticaria

InflaRx N.V. reported positive Phase 2a data for INF904 in hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU). Efficacy data were reported from 29 of 31 HS patients and 30 of 31 CSU patients. The study showed rapid and consistent reductions in ANs and dTs, improvements in measures such as HiSCR, IHS4, NRS30, and DLQI. Safety data from 33 HS patients showed no signal of safety concern, with no serious adverse events reported. InflaRx believes these data provide strong rationale for further development in both indications.